EUVIMEDEUVIMED entdecken
Crossref

Interferon Regulatory Factor 4: An Alternative Marker for Plasma Cells in Daratumumab‐Treated Patients With Multiple Myeloma

Suwen Yang iD, Qianwen Hu, Xiaofen Wang, Sai Qiao, Chao Qi, Hong Jin, Yuhong Zhong

International Journal of Laboratory Hematology · 2025

DOI: 10.1111/ijlh.14366 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Laboratory Hematology, 2025. Verfasst von Suwen Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Laboratory, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Monoclonal, Interferon Regulatory Factors, Plasma Cells. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Medical and Health Science and Technology Program of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Anti‐CD38 therapeutic modalities (e.g., daratumumab) can impede classical CD38 and CD138 gating use for plasma cell (PC) detection in multiple myeloma (MM) patients with minimal residual disease (MRD). We assessed the applicability of CD229, CD269, and interferon regulatory factor (IRF‐4) for PC detection in MM MRD patients.

Methods

Bone marrow samples were collected from patients with MM. Through multiparameter flow cytometry, we evaluated the suitability of CD229, CD269, and IRF‐4 for distinguishing PCs from other hematopoietic cells and compared their expression pattern on normal PCs (nPCs) and aberrant PCs (aPCs). We also assessed IRF‐4 expression stability after sample storage under different conditions. A 10‐color MRD antibody panel was used to determine whether IRF‐4 is an alternative primary PC‐gating marker for MM MRD assessment.

Results

IRF‐4 was expressed specifically on all PCs; its mean fluorescence intensity (MFI) was highest on PCs among all hematopoietic cells. This MFI did not decrease even after sample storage at 4°C or 25°C for 72 h. In all 42 MRD assessment samples, except for samples ( n = 10) with no PCs, the use of IRF‐4 enabled accurate nPC ( n = 12), aPC ( n = 13), and nPC + aPC ( n = 7) identification. Even samples from daratumumab‐treated patients had high IRF‐4 MFI, with no difference between pre‐treatment and post‐treatment ( n = 7; p = 0.610).

Conclusions

IRF‐4 demonstrates high MFI on PCs, and it is not expressed on other leukocytes. In MM patients with MRD, daratumumab treatment does not affect IRF‐4 expression. IRF‐4 is a promising marker for PC identification in MRD assessment of MM patients undergoing anti‐CD38 therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntibodies, MonoclonalInterferon Regulatory FactorsPlasma CellsBiomarkers, TumorHumansNeoplasm, ResidualMaleFemaleMiddle AgedFlow CytometryAgedInterferon Regulatory Factor-4

Stichwörter der Autor:innen

daratumumabinterferon regulatory factor 4minimal residual diseasemultiparameter flow cytometrymultiple myeloma

Substanzen

Antibodies, MonoclonalInterferon Regulatory FactorsBiomarkers, TumorInterferon Regulatory Factor-4daratumumab

Autor:innen und Institutionen

  • Clinical Laboratory, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
  • Key Laboratory of Precision Medicine in Diagnosis and Monitoring Research of Zhejiang Province, Hangzhou, Zhejiang, China.

ORCID-Profile: Suwen Yang

Förderung

  • Medical and Health Science and Technology Program of Zhejiang Province

Zitieren

APA

Yang, S., Hu, Q., Wang, X., Qiao, S., Qi, C., Jin, H., & Zhong, Y. (2025). Interferon Regulatory Factor 4: An Alternative Marker for Plasma Cells in Daratumumab‐Treated Patients With Multiple Myeloma. International Journal of Laboratory Hematology. https://doi.org/10.1111/ijlh.14366

Vancouver

Yang S, Hu Q, Wang X, Qiao S, Qi C, Jin H, et al. Interferon Regulatory Factor 4: An Alternative Marker for Plasma Cells in Daratumumab‐Treated Patients With Multiple Myeloma. International Journal of Laboratory Hematology. 2025. doi:10.1111/ijlh.14366

BibTeX
@article{Yang2025,
  author = {Yang, Suwen and Hu, Qianwen and Wang, Xiaofen and Qiao, Sai and Qi, Chao and Jin, Hong and Zhong, Yuhong},
  title = {Interferon Regulatory Factor 4: An Alternative Marker for Plasma Cells in Daratumumab‐Treated Patients With Multiple Myeloma},
  journal = {International Journal of Laboratory Hematology},
  year = {2025},
  doi = {10.1111/ijlh.14366}
}
Kostenlos starten →